Dr Jean-Paul Bahary, M.D., F.R.C.P.,M.Sc.

Full professor;
Department of Radio-oncology (CHUM);
Faculty of Medicine (UofM);
CRCHUM and Institut du cancer de Montréal.

 

Key words: Abbott, CARO, Pfizer, CIHR, FRSQ, RTOG, NCIC

1987-1990  Residency in radio-oncology et chief resident, University of McGill

1991  Fellowship, radio-oncology program, Supervisor: Dr D.A. Larson, University of California, San Francisco, California (USA)

1997  Medical-administrative training. Association des C.M.D.P. du Québec

2008-2010  Forces Program/Extra

2010-2013  Masters in health administrationFaculty of Medicine, University of Montréal

2011-2015  FRQS Chercheur boursier : Junior 1 

2001  Education scholarship, Abbott Canada

2001  Abbott Canada Scholarship for the support of radiation oncology research

  • 2012-2017  (co-PI) Operating grant, Instituts de recherche en santé du Canada (IRSC)

    “Rheumatoid arthritis and immune dysfunctions”: The role of damaged hematopoietic stem and progenitor cells”

  • 2012–2017 (co-PI)  Canadian Institutes of Health Research (CIHR)

    "A randomized trial comparing a conventional course with a short course of external beam radiotherapy for the treatment of intermediate risk prostate cancer (Profit II)"

  • 2010–2015 (co-chercheur) Canadian Institutes of Health Research (CIHR)

    "A randomized trial of a shorter radiation fraction schedule for the treatment of localized prostate cancer"

  • Mai 2010– avril 2013 (co-PI) FRSQ (Fonds de la recherche en santé du Québec)

    "Évaluation de l’impact potentiel d’un centre Québécois de protonthérapie pour les jeunes survivants de cancer"

  • 2009 (PI) Radiation Therapy Oncology Group (RTOG)

    "A randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer (RTOG 0938)"

  • 2009-2011 (co-PI) CIHR et NCIC

    "A national study, “Patterns of Care” study”, radiation treatment for prostate cancer : use and development of quality indicators"

  • Janvier 2009 – Octobre 2011 (PI) Pfizer Canada Inc

    "Abandon du tabac chez les patients atteints de cancer du poumon et chez leurs proches fumeurs”

  • Avril 2007 (co-PI) Institut national du cancer du Canada, Groupe des essais cliniques

    "Étude de phase I portant sur l'administration de la combinaison Témozolomide et RAD001C à des patients qui ont un glioblastome multiforme".

 

Awards

2004  Best oral presentation 2nd place, Congrès de l’Association des Neurochirurgiens du Québec, Hull, Québec

2005  Best poster presentation, Montreal Center for Experimental Therapeutics in Cancer, Montreal

2009  Distinction - CARO Lecturer 2009, Collège royal des médecins et chirurgiens du Canada, at the annual meeting for the Association des radio-oncologues du Canada  (Québec)

2013-2013 Prix du nouvel investigateur, The Terry Fox Research Institute

  • Clinical research in nervous system and prostate neoplasias

  • Translational research 

  • Using informational tools in cancer screening

     

Current projects (techniques used):

Multiple research projects with NRG, RTOG and NCIC

 

Associated websites:

  1. CRCHUM webpage

  2. UofM webpage

  3. Research Gate

 

Pharma Collaborators:

  • Johnson et Johnson

 

 

 

  1. Bruner DW, Hunt D, Michalski JM, Bosch WR, Galvin JM, Amin M, Xiao C, Bahary JP, Patel M, Chafe S, Rodrigues G, Lau H, Duclos M, Baikadi M, Deshmukh S, Sandler HM:    Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. 
 Cancer. 2015 Jul 15;121(14):2422-30. doi: 10.1002/cncr.29362. Epub 2015 Apr 2.PMID: 25847819.

  2. Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, Kirkbride P, Parliament M, Moynihan C, Bahary JP, Parmar MK, Sanders K, Chen BE, Mason MD: Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. 
 J Clin Oncol. 2015 Jul 1;33(19):2151-7. doi: 10.1200/JCO.2014.57.8724. Epub 2015 May 26.PMID: 26014295.

  3. Krauss DJ, Hu C, Bahary JP, Souhami L, Gore EM, Chafe SM, Leibenhaut MH, Narayan S, Torres-Roca J, Michalski J, Zeitzer KL, Donavanik V, Sandler H, McGowan DG, Jones CU, Shipley WU:    Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. 
  Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):863-73. doi: 10.1016/j.ijrobp.2015.03.017. Epub 2015 Mar 25.PMID: 26104939.

  4. Justin C. Voog, Rebecca Paulus, William U. Shipley, Matthew R. Smith, David G. McGowan, Christopher U. Jones, Jean-Paul Bahary, Kenneth L. Zeitzer, Luis Souhami, Mark H. Leibenhaut, Marvin Rotman, Siraj M. Husain, Elizabeth Gore, Adam Raben, Susan Chafe, Howard M. Sandler, Jason A. Efstathiou:     Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. 
  Journal of European Urology EURURO-6390; No. of Pages 7.

  5. Michel Zimmermann, Daniel Taussky, Menkarios C, Éric Vigneault, Marie-Claude Beauchemin, Jean-Paul Bahary, Martin AA, Diaz de Bedoya LV, Carole Lambert:  Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes - DOI: http://dx.doi.org/10.1016/j.clon.2015.12.024 - Clinical Oncology, Jan 2016.